Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Electronic Arts Inc. stock logo
EA
Electronic Arts
$209.70
$208.88
$159.10
▼
$210.20
$52.93B0.645.04 million shs48.63 million shs
Incyte Corporation stock logo
INCY
Incyte
$119.09
-1.0%
$118.94
$89.25
▼
$132.60
$24.51B0.781.77 million shs2.25 million shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Electronic Arts Inc. stock logo
EA
Electronic Arts
0.00%0.00%0.00%0.00%+4.45%
Incyte Corporation stock logo
INCY
Incyte
-0.98%-1.01%+5.32%-7.30%+14.32%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Electronic Arts Inc. stock logo
EA
Electronic Arts
$209.70
$208.88
$159.10
▼
$210.20
$52.93B0.645.04 million shs48.63 million shs
Incyte Corporation stock logo
INCY
Incyte
$119.09
-1.0%
$118.94
$89.25
▼
$132.60
$24.51B0.781.77 million shs2.25 million shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Electronic Arts Inc. stock logo
EA
Electronic Arts
0.00%0.00%0.00%0.00%+4.45%
Incyte Corporation stock logo
INCY
Incyte
-0.98%-1.01%+5.32%-7.30%+14.32%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Electronic Arts Inc. stock logo
EA
Electronic Arts
1.80
Reduce$204.00-2.72% Downside
Incyte Corporation stock logo
INCY
Incyte
2.44
Hold$133.8612.40% Upside

Current Analyst Ratings Breakdown

Latest INCY and EA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Incyte Corporation stock logo
INCY
Incyte
Set Price TargetHold$115.00
11/12/2026
Incyte Corporation stock logo
INCY
Incyte
UpgradeStrong Sell ➝ Hold
11/5/2026
Incyte Corporation stock logo
INCY
Incyte
Lower Price TargetOutperform$154.00 ➝ $150.00
11/4/2026
Incyte Corporation stock logo
INCY
Incyte
DowngradeBuy (B) ➝ Hold (C)
11/2/2026
Incyte Corporation stock logo
INCY
Incyte
Boost Price TargetMarket Perform$104.00 ➝ $108.00
10/30/2026
Incyte Corporation stock logo
INCY
Incyte
Set Price Target$152.00
10/30/2026
Incyte Corporation stock logo
INCY
Incyte
Lower Price TargetEqual Weight$128.00 ➝ $127.00
10/30/2026
Incyte Corporation stock logo
INCY
Incyte
Boost Price TargetSector Perform$114.00 ➝ $117.00
10/30/2026
Incyte Corporation stock logo
INCY
Incyte
Boost Price TargetOverweight$139.00 ➝ $143.00
10/27/2026
Incyte Corporation stock logo
INCY
Incyte
Reiterated RatingMarket Perform
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Electronic Arts Inc. stock logo
EA
Electronic Arts
$7.53B7.03N/AN/A$28.05 per share7.48
Incyte Corporation stock logo
INCY
Incyte
$5.14B4.72$6.12 per share19.46$27.68 per share4.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Electronic Arts Inc. stock logo
EA
Electronic Arts
$887M$3.4949.23N/AN/A13.80%22.45%11.48%N/A
Incyte Corporation stock logo
INCY
Incyte
$1.29B$1.8863.3515.024.386.71%7.92%6.12%N/A

Latest INCY and EA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Incyte Corporation stock logo
INCY
Incyte
-$3.93-$3.60+$0.33-$3.86$1.46 billion$1.56 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Electronic Arts Inc. stock logo
EA
Electronic Arts
$0.760.36%+17.45%21.78%N/A
Incyte Corporation stock logo
INCY
Incyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Electronic Arts Inc. stock logo
EA
Electronic Arts
0.21
1.21
1.05
Incyte Corporation stock logo
INCY
Incyte
N/A
3.84
3.75

Institutional Ownership

CompanyInstitutional Ownership
Electronic Arts Inc. stock logo
EA
Electronic Arts
90.23%
Incyte Corporation stock logo
INCY
Incyte
96.97%

Insider Ownership

CompanyInsider Ownership
Electronic Arts Inc. stock logo
EA
Electronic Arts
0.24%
Incyte Corporation stock logo
INCY
Incyte
16.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Electronic Arts Inc. stock logo
EA
Electronic Arts
12,900252.39 million251.78 millionOptionable
Incyte Corporation stock logo
INCY
Incyte
2,844203.83 million170.81 millionOptionable

Recent News About These Companies

Incyte (NASDAQ:INCY) EVP Sells $1,292,049.08 in Stock
INCY Wins European Commission Nod For Skin Disease Drug
Incyte Wins EU Approval for HS Drug
Incyte wins EU approval for povorcitinib to treat skin condition
Incyte (NASDAQ:INCY) Upgraded to "Hold" at Zacks Research
NHS use of Incyte's anal cancer drug Zynyz backed by NICE
Incyte (NASDAQ:INCY) CMO Sells $28,436,449.27 in Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Electronic Arts stock logo

Electronic Arts NASDAQ:EA

Electronic Arts Inc. develops, markets, publishes, and distributes games, content, and services for game consoles, PCs, mobile phones, and tablets worldwide. It develops and publishes games and services across various genres, such as sports, racing, first-person shooter, action, role-playing, and simulation primarily under the Battlefield, The Sims, Apex Legends, Need for Speed, and license games from others, including FIFA, Madden NFL, UFC, and Star Wars brands. The company licenses its games to third parties to distribute and host its games. It markets and sells its games and services through digital distribution and retail channels, as well as directly to mass market retailers, specialty stores, and distribution arrangements. Electronic Arts Inc. was incorporated in 1982 and is headquartered in Redwood City, California.

Incyte stock logo

Incyte NASDAQ:INCY

$119.09 -1.18 (-0.98%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$114.75 -4.34 (-3.64%)
As of 09:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.